Via News Knowledge File

AbbVie Inc.

organization80% conf.·synced Aug 13, 2026

Biopharmaceutical company based in North Chicago, Illinois, developing oncology and hematology therapeutics

sourced metrics

521

relationships

stated objectives

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price

248.76USD

Aug 12, 2026reference only

Price 52 Week High

263.30USD

Aug 12, 2026reference only

Stock Return Ytd

8.5%

Aug 12, 2026reference only

Price 52 Week Low

197.38USD

Aug 12, 2026reference only

Net Income

3613000000.0USD

Jun 30, 2026reference only

Capex

587000000.0USD

Jun 30, 2026reference only

Cash

6569000000.0USD

Jun 30, 2026reference only

Stockholders Equity

-5935000000.0USD

Jun 30, 2026reference only

Cost Of Revenue

4291000000.0USD

Jun 30, 2026reference only

Total Assets

135115000000.0USD

Jun 30, 2026reference only

Revenue

16990000000.0USD

Jun 30, 2026reference only

Eps

2.03USD_per_share

Jun 30, 2026reference only

Operating Income

6432000000.0USD

Jun 30, 2026reference only

Operating Cash Flow

7265000000.0USD

Jun 30, 2026reference only

Consecutive Dividend Increases

53years

May 25, 2026source

Mid Late Stage Clinical Trials

60programs

May 25, 2026source

Pipeline Total Programs

90programs

May 25, 2026source

Portfolio Weight In Xlv

7.09percent

May 18, 2026source

Stated objectives

Develop and commercialize 35+ investigational medicines in multiple clinical trials across hematologic cancers

source

target: 35 stated

Pursue additional international regulatory approvals for the R/R FL indication

source

stated

Evaluate epcoritamab as monotherapy and in combination across lines of therapy in a range of hematologic malignancies through four ongoing Phase 3 trials

source

stated

Achieve adjusted diluted EPS for 2025

source

target: 12.12 to 12.32 USD by 2025-12-31 00:00:00stated

Achieve high single-digit compound annual revenue growth rate for ex-Humira platform

source

target: high single-digit percent by 2029-12-31 00:00:00stated

Achieve combined sales of immunology duo

source

target: 27 billion USD by 2027-12-31 00:00:00stated

Raised full-year earnings guidance

source

target: $10.61-$10.65 EPS by 2025-12-31 00:00:00stated

High single-digit CAGR through 2029

source

target: high single-digit percent CAGR by 2029-01-01 00:00:00stated

Drive long-term growth through early-stage pipeline development

source

stated

Return to robust revenue growth following Humira LOE

source

by 2025-01-01 00:00:00stated

Relationship graph · 521 connections

Developed by

245

Competes with

Covered by

headquartered in

Employs

regulates

acquired by

Invested in

Via News coverage

Four Oncology Drugs Face FDA PDUFA Decisions in 2026, Stacking Binary Catalyst Risk Into a Narrow Window

June 19, 2026

FDA H2 2026 Oncology Docket Packs Four Major Decisions Into One Catalyst Window

June 17, 2026

Jade Biosciences JADE301 Phase 1 Trial Set for March 2027 Start in Autoimmune Space

February 21, 2026

Dividend Stocks Offer Steady Income but Come with Risks

January 19, 2026

AbbVie Strikes Deal to Cut Drug Prices, Boost U.S. R&D Investment

January 13, 2026

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →